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Abstract
Type 2 diabetes mellitus is one of the major public health threats in the United States today, reaching
epidemic rates. Epidemiological evidence suggests a strong link between obesity and the risk of
developing diabetes. Increasing evidence demonstrates that lifestyle interventions can significantly
delay or possibly prevent the onset of type 2 diabetes in persons with increased risk. Despite these
findings, there remain important barriers to the translation of this research to the public health. These
include identifying persons with an increased risk for developing the disease and the lack of easily
accessible, cost-effective intervention programs. At least one study, however, has effectively
implemented an evidenced-based intervention in community settings, suggesting that it may be
possible to develop a model for the national scalability of primary prevention in the United States.
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Type 2 diabetes mellitus is one of the major public health threats in the United States today. There are
currently 24 million Americans estimated to have diabetes. Moreover, there are over 65 million
Americans with evidence of “prediabetes,” characterized by evidence of a metabolic defect defined by
the presence of either impaired glucose tolerance (IGT) or impaired fasting glucose. Persons with
prediabetes have a significantly increased risk for developing type 2 diabetes—between 5 and 15% per
year depending on the presence of other risk factors.  These statistics illuminate a frightening
possibly; the number of persons with diabetes is expected to nearly double by 2030 if current trends
continue unabated.
Epidemiological evidence suggests a strong link between obesity and the risk of developing diabetes.
Figure 1 shows data combined from two studies, the Nurses Health Study  and the U.S. Health
Professionals Study.  Both are longitudinal studies that look at the effect of lifestyle on chronic
illness. In the male health professional study, men with a body mass index (BMI) greater than 35
had an age-adjusted risk of 42.1 times greater than a man with a BMI of less than 23 for developing
diabetes. A similar trend was observed in female nurses, with the risk increasing to a staggering 93.2 of
developing diabetes with a BMI of greater than 35 kg/m . Moreover, the longer a person remains
1–5
1,3,5,6
4,5
7–10
11
12,13
2
Personalized Medicine for Diabetes: The Prevention of Type 2 Diabetes: ... http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769939/
1 of 10 8/27/2013 11:30 AM
obese, the higher their risk of developing type 2 diabetes. In one study, people who have been at a BMI
of greater than 30 for more than 10 years have over twice the risk of type 2 diabetes compared with
those who have been obese for less than 5 years.
Fortunately, three major clinical trials have demonstrated convincingly that personalized lifestyle
interventions can significantly delay or possibly prevent the onset of type 2 diabetes in persons with
prediabetes. The first was the Da Qing study, which screened over 110,000 men and women for IGT in
33 health centers in China.  The investigators identified 577 persons (mean age 45 and mean BMI
25.8 kg/m ) with IGT and randomized them by clinic to receive either standard care (i.e., the control
condition) or one of three interventions: diet only, exercise only, or a combined diet and exercise
intervention. These interventions were selected to address insulin resistance via weight loss and
physical activity. Each of the interventions was personalized to accommodate subjects' lifestyle and
situation. In the diet-only condition, subjects were encouraged to eat a diet that provided
approximately 55–65% of total daily calories from carbohydrate, increased consumption of vegetables
while reducing simple sugars and alcohol, and were within a calorie goal of 25–30 kcal per kilogram of
body weight. Subjects consulted individually with physicians and in small groups to achieve these
goals. The exercise intervention was also tailored to subject's level of fitness. They were encouraged to
increase the amount of their leisure physical exercise by one “unit” per day. Units were defined as
either 30 minutes of mild, 20 minutes of moderate, 10 minutes of strenuous, or 5 minutes of very
strenuous exercise. As was the case in diet intervention, the exercise prescription was personalized to
account for differences in subject's level of fitness and capacity. The diet plus exercise intervention
simply combined the two personalized approaches.
After 6 years of observation, the Da Qing study showed a 31% reduction in risk of developing diabetes
for the diet intervention, a 46% reduction for the exercise intervention, and a 41% reduction for the
combined diet and exercise intervention. This was the first study that clearly demonstrated that
implementing a personalized lifestyle intervention was both feasible and effective for the prevention of
type 2 diabetes.
The next major clinical trial of lifestyle as a prevention modality for type 2 diabetes was the Finish
Diabetes Prevention (FDP) study.  The FDP recruited and randomized 522 adults age 40–65 with IGT
to receive either a control or a lifestyle intervention. Subjects assigned to the control condition received
written and oral general information about a weight loss diet and benefits of exercise provided at
baseline and annually. They also completed a 3-day food diary annually, but this was used for data
collection purposes only. Subjects assigned to the intervention condition were provided detailed,
individualized instructions on achieving study goals: weight loss of at least 5% of their body weight at
entry into the study, a reduction in total daily calories derived from fat to 30%, an increase in fiber
intake to ≥15 g/1000 kcal, and moderate exercise for at least 30 minutes per day. This was
accomplished by meeting with a registered dietician seven times in the first year and quarterly
thereafter. In addition, supervised exercise programs were offered. At the end of 4 years, subjects in the
intervention condition showed a 58% reduction in risk of developing diabetes compared to controls.
The largest and most rigorous prevention trial to date is the Diabetes Prevention Program (DPP).  The
DPP recruited 3234 subjects age 25–75 with IGT. In addition, unlike the studies reviewed earlier,
which studied subjects with homogeneous characteristics, almost half of the DPP subjects were from
minority groups. Subjects were randomized into one of three conditions: an intensive lifestyle
intervention, a medication intervention, or a medication placebo control condition. Subjects in the
lifestyle intervention were encouraged to lose at least 7% of their initial body weight and to maintain
this weight loss throughout the trial. The primary method advocated for weight loss was to reduce fat
intake to 25% of total daily calories and restrict daily caloric consumption. In addition, each participant
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was encouraged to achieve and maintain at least 150 minutes per week of physical activity, with an
intensity similar to brisk walking. Subjects in the medication arm were given metformin and were
recommended to maintain a healthy lifestyle but without specific advice as to how to accomplish this.
Control subjects were given placebo metformin and were also provided the same lifestyle
recommendations.
At the end of 3 years, trial data warranted an early termination of the study. Subjects in the lifestyle
condition had a 58% reduction in risk of developing diabetes, and subjects in the medication arm had a
31% reduction when compared to control subjects. In addition, the interventions were effective
regardless of race or age.
Since the DPP, at least four trials have been conducted that reinforce the ability of lifestyle
modification to significantly reduce the risk of developing diabetes in persons with prediabetes.
Collectively, if results of the primary prevention trials that assessed lifestyle interventions are pooled,
they average a 51% reduction in risk (Figure 2). Moreover, all of these studies have demonstrated that
to be effective, the intervention programs must be personalized to meet the unique situational and
cultural aspects of its recipients.
So why don't we have a diabetes prevention program on every street corner? Simply put, in the United
States today, there remain important barriers to the translation of the DPP to public health. First, to
develop an evidenced-based program, it is important to identify persons with prediabetes. While there
are a variety of pen and paper methods to assess risk, the gold standard is still a blood test identifying
prediabetes, either by fasting glucose values or, more appropriately, an oral glucose tolerance test to
define impaired glucose tolerance. Currently, performing such tests is not routine in primary care
settings. Indeed, only recently were primary care physicians able to be reimbursed for screening for
prediabetes.
The second and perhaps more problematic barrier is the lack of established lifestyle intervention
programs. Lifestyle interventions are resource and time intensive, exceeding both the resources and the
training of most primary care providers. In addition, implementing programs such as the one used in
the DPP is costly. Thus, it begs the question, why screen for prediabetes if there is no reasonable,
cost-effective way to treat those who screen positive?
Clearly to overcome these barriers and provide “real-world” implementation, it will be necessary to
simplify testing to identify high-risk patients and provide lower cost, more easily accessible
evidence-based interventions. This will require that new partnerships be developed between health
care systems, where diabetes risk can be assessed accurately and community agencies where the
necessary resources to mount more accessible, long-term lifestyle interventions are available.
One example of this partnership approach has been pilot tested by the Diabetes Translational
Research Center (DTRC) at the Indiana University School of Medicine. The DTRC tested the feasibility
and effectiveness of training Young Men's Christian Association (YMCA) employees to deliver a
group-based version of the DPP lifestyle intervention in YMCA branch facilities.  The YMCA was
selected for its ability to address the barriers to translation described earlier. The intervention model
used in the DPP was adapted for delivery in groups using lower cost “lay leaders” employed by the
YMCA. In addition, programs can be implemented at reduced expense because the YMCA operates on a
cost recovery basis rather than for profit. In addition, the YMCA has the potential for considerable
reach; there are over 2600 YMCAs in the United States with over 46 million persons living within 3
miles of a YMCA facility.
The study was a control trial in which YMCA facilities were randomized to receive either the
group-based adaptation of the DPP or counseling regarding how persons identified as being at high
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risk could individually reduce their risk using materials developed by the National Diabetes Education
Program (NDEP). Risk assessment was done by mailing brochures to households within 5 km of
the participating YMCAs, inviting them to attend a diabetes risk screening event held at the YMCA
facility. This screening event was staffed by members of the Indiana University School of Medicine. All
participants were tested for BMI and blood pressure; random or casual capillary glucose, cholesterol,
and hemoglobin A1c levels were assessed using point-of-care technology. In combination with their
responses to a family history of diabetes, levels of physical activity, and age, a risk score was assigned.
Those deemed being a high risk were either enrolled in the group adaptation of the DPP curriculum
delivered by trained YMCA staff or received brief counseling regarding the meaning of their risk
assessment data by medical staff conducting the screening event. This counseling was supported by
NDEP materials.
The cost for delivering the 16 session DPP curriculum using the YMCA was a fraction of that required
when the original DPP intervention was implemented; $205 dollars per participant vs $1476 required
in the original study. Is it possible for the YMCA to achieve a 5–7% weight loss for a fraction of the cost
of the DPP? Tables 1 and 2 show outcome data for this pilot. Subjects in the group intervention
achieved a 6% weight loss that was maintained at 6 and 14 months postintervention contact. Moreover,
data show a significant reduction in total cholesterol over the same time period.
Convincing evidence demonstrates that implementing personalized programs to help persons adopt
risk-reducing lifestyle behaviors can help reduce the epidemic of type 2 diabetes. Data from the YMCA
study suggest that it may be possible to develop a model for the national scalability of primary
prevention in the United States. Such a model should combine a community agency such as the YMCA
in collaboration with medical centers to address the current barriers to translation of the DPP in the
United States so that evidence-based, cost-effective primary prevention programs can be implemented.
Abbreviations
BMI body mass index
DPP Diabetes Prevention Program
DTRC Diabetes Translational Research Center
FDP Finish Diabetes Prevention
IGT impaired glucose tolerance
NDEP National Diabetes Education Program
YMCA Young Men's Christian Association
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Figure 1.
Obesity and type 2 diabetes.
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Figure 2.
Reduction in type 2 diabetes—lifestyle intervention trials. FinDPS, Finnish Diabetes Prevention Study; IDDP, Indian
Diabetes Prevention Program; RCTs, randomized controlled trials. Adapted from Gillies and colleagues.17
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Table 1.
Results of DTRC–YMCA Study after 4–6 Months Postintervention
Brief advice (N = 38) DPP (N = 39) p value
Weight (% reduction) −2.0 −6.0 <0.001
Change systolic blood pressure (mmHg) −2.3 −1.9 0.88
Change hemoglobin A1c (%) −0.1 −0.1 0.96
Change total cholesterol (mg/dl) +6.0 −21.6 <0.001
Change high-density lipoprotein (mg/dl) +2.1 +1.1 0.68
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Table 2.
Results of DTRC–YMCA Study after 12–14 Months Postintervention
Brief advice (N = 33) DPP (N = 29) p value
Weight (% reduction) −1.8 −6.0 0.008
Change systolic blood pressure (mmHg) −2.7 −1.6 0.78
Change hemoglobin A1c (%) +0.03 −0.1 0.28
Change total cholesterol (mg/dl) +11.8 −13.5 0.002
Change high-density lipoprotein (mg/dl) −1.4 +1.9 0.10
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